Lipocine LPCN 深 滬
已收盤 08-29 16:00:00 美东时间
2.91
-0.070
-2.35%
華盛通- 最 高2.98
- 今 開2.98
- 成交量 1.49万股
- 最 低 2.8647
- 昨 收 2.98
- 總市值 1576.93万
- 52周最高 6.1683
- 市盈率 靜 --
- 換手率 0.27%
- 52周最低 2.6838
- 委 比 -42.86%
- 總股本 541.90万
- 歷史最高 340.00
- 量 比 0.71
- 振 幅 3.87%
- 歷史最低 2.6838
- 每 手 1
- 風險率 0.87%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025
SALT LAKE CITY, Aug. 26, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with eff...
08-26 20:00
HC Wainwright & Co. Reiterates Buy on Lipocine, Maintains $8 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Lipocine (NASDAQ:LPCN) with a Buy and maintains $8 price target.
08-20 21:11
Lipocine Q2 EPS $(0.41) Misses $(0.40) Estimate, Sales $622.849M Beat $229.000K Estimate
Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.40) by 2.5 percent. This is a 26.79 percent increase over losses of $(0.56) per share from the same
08-05 20:17
Lipocine Hosts Virtual Event on LPCN 1154
The latest update is out from Lipocine ( ($LPCN) ). On July 9, 2025, Lipocine h...
07-09 23:28
Lipocine Updates Corporate Presentation for Investors
Lipocine ( ($LPCN) ) just unveiled an announcement. Lipocine has updated its co...
07-02 23:48
Lipocine Begins Phase 3 Trial for LPCN 1154
An announcement from Lipocine ( ($LPCN) ) is now available. On June 26, 2025, L...
06-26 21:57
Lipocine to Host R&D Event on July 9
Lipocine ( ($LPCN) ) has provided an update. Lipocine Inc. announced it will ho...
06-24 02:57
美股大行评级 | 潜在涨幅434.95%！VNRX获Jones Trading首予"买入"评级，目标价3美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1139478829918380033.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持Metsera(MTSR)"买入"评级，目标价从56美元升至62美元</p> <p>• 摩根大通：维持Avidity Biosciences(RNA)"超配"评级，目标价从57美元升至59美元</
06-11 09:43
Lipocine’s Partner Files New Drug Submission in Canada
Lipocine ( ($LPCN) ) has shared an update. On June 9, 2025, Lipocine announced ...
06-09 18:28
Lipocine's Licensing Partner, Verity Pharma, Filed A New Drug Submission For Tlando In Canada, Tlando Is The First And Only Oral Testosterone Replacement Therapy Option Approved By FDAThat Does Not Require Dose Titration
New Drug Submission filed by Lipocine's licensing partner Verity PharmaOver 700,000 total prescriptions written annually for testosterone replacement therapy (TRT) in Canada, representing large commercial opportunity
06-09 18:25
